CureVac (NASDAQ:CVAC - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $5.72 and last traded at $5.60, with a volume of 22916470 shares traded. The stock had previously closed at $4.07.
Wall Street Analyst Weigh In
CVAC has been the subject of a number of research reports. JMP Securities restated a "market outperform" rating and issued a $10.00 target price on shares of CureVac in a research note on Wednesday, May 28th. Jefferies Financial Group reissued a "hold" rating and issued a $5.00 target price (down from $7.00) on shares of CureVac in a research note on Friday. Citigroup lowered CureVac to a "market perform" rating in a research note on Thursday. Finally, UBS Group lowered their price target on shares of CureVac from $13.00 to $12.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th.
View Our Latest Stock Report on CureVac
CureVac Price Performance
The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The company has a 50 day simple moving average of $3.82 and a 200 day simple moving average of $3.51. The stock has a market cap of $1.24 billion, a P/E ratio of 10.04 and a beta of 2.49.
CureVac (NASDAQ:CVAC - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). The business had revenue of $0.94 million during the quarter, compared to the consensus estimate of $4.27 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. Sell-side analysts forecast that CureVac will post 0.72 earnings per share for the current fiscal year.
Hedge Funds Weigh In On CureVac
Several hedge funds have recently modified their holdings of the stock. Greenleaf Trust acquired a new position in CureVac during the first quarter valued at approximately $31,000. Integrated Wealth Concepts LLC increased its holdings in CureVac by 25.0% during the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock worth $42,000 after buying an additional 3,000 shares during the last quarter. Two Sigma Advisers LP bought a new stake in CureVac during the fourth quarter worth $48,000. Jump Financial LLC acquired a new stake in CureVac in the fourth quarter valued at $55,000. Finally, D. E. Shaw & Co. Inc. bought a new position in shares of CureVac in the 4th quarter valued at about $66,000. Institutional investors own 17.26% of the company's stock.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Stories
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
